Summary
Objectives
To analyse applications to the London multicentre research ethics committee (MREC) for duration, efficiency and outcome of the ethical review process.
Design and setting
Retrospective review of applications for the period October 1997–November 2000, from discussion at first announced meeting to outcome.
Source data
Completed application forms, minutes of meetings, and correspondence between the MREC and researchers.
Results
Of 353 applications, 14 (4%) were approved, 217 (62%) were conditionally approved, 103 (29%) were deferred, and 19 (5%) were rejected at first meeting. All deferred and rejected applications were reconsidered at up to four other meetings and required more profound changes than conditionally approved applications. Most applications required changes to the patient information leaflet. A total of 330 (93%) applications were approved eventually. The estimated median time from first meeting to approval was 64 days (range 7–386).
Conclusions
The review process was facilitative, rigorous and often protracted. More care and effort in preparing applications, particularly the patient information leaflet, would improve the success rate. When the European Clinical Trials Directive (CTD) is implemented, the MREC will have to either shorten the approval time of some applications or reject more applications.
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1097%2F00124363-200210000-00002/MediaObjects/40290_2012_16050209_Tab1.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1097%2F00124363-200210000-00002/MediaObjects/40290_2012_16050209_Tab2.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1097%2F00124363-200210000-00002/MediaObjects/40290_2012_16050209_Tab3.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1097%2F00124363-200210000-00002/MediaObjects/40290_2012_16050209_Tab4.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1097%2F00124363-200210000-00002/MediaObjects/40290_2012_16050209_Tab5.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1097%2F00124363-200210000-00002/MediaObjects/40290_2012_16050209_Tab6.jpg)
Similar content being viewed by others
References
NHS Management Executive Circular HSG (97) 23. Ethics committee review of multicentre research. London: Department of Health, 1997.
MRECs. Constitution, May 1997.
MRECs. General guidance for researchers, November 1997. Revised April 2000. http://www.corec.org.uk
Foster C. The current status of ethical review procedures in the United Kingdom. Int J Pharm Med 1997; 11:155–159.
Holley S, Foster C. Ethical review of multicentre research: a survey of local research in South Thames region. J R Coll Physicians Lond 1998; 32:238–245.
Stacey TE. Ethical review in the NHS: the need for change. J R Coll Physicians Lond 1998; 32:190–192.
Evered D. Development of MRECs in the UK. Int J Pharm Med 1998; 12:141–145.
Carter D, Calman K. Department of Health, 18 January 1998.
Stacey T. NHS Executive, September 1998.
MREC guidelines for researchers: patient information sheet and consent form. http://www.corec.org.uk
Al-Shahi R, Warlow CP. Ethical review of a multicentre study in Scotland: a weighty problem. J R Coll Physicians Lond 1999; 33:549–552.
Tully J, Ninis N, Booy R, Viner R. New system of review by MRECs: prospective study. Br Med J 2000; 320:1179–1182.
Lux AI, Edwards SW, Osborne JP. Responses of LRECs to a study with approval from a MREC. Br Med J 2000; 320:1182–1183.
Evans D. The reform of multicentre ethical review: MRECs for better or for worse. Int J Pharm Med 1997; 11:217–220.
Commentary. Multiple centre research and ethical review. Int J Pharm Med 1997; 11: 191.
Commentary. Concerns over multiple ethics committees remain. Int J Pharm Med 1999; 13: 120–121.
Jaderberg ME. One year of the MREC system: did the UK research community shoot itself in the foot? Int J Pharm Med 1999; 13:159–161.
Alberti KGMM. MRECs: has the cure been worse than the disease? Br Med J 2000; 320:1157–1158.
Jaderberg ME. UK ethics review system: concerns and frustrations. Good Clin Pract J 2001; 8:24–28.
Tiner R. Cited in Bull Med Ethics 2000; 159:4.
Report into the research framework in North Staffordshire. Bull Med Ethics 2000; 158:20–24.
Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Off J Eur Comm 2001; L121:34–44.
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Harmonised Tripartite Guideline for Good Clinical Practice, 1996. CPMP/ICH/135/95/Step5. http://www.emea.eu.int
Governance Arrangements for NHS Research Ethics Committees. Central Office for Research Ethics Committees. July 2001. http://www.corec.org.uk
Nicholson R. What do they get up to? LREC annual reports. Bull Med Ethics 1997; 129:13–24.
Kent G. Responses by four LRECs to submitted proposals. J Med Ethics 1999; 25:274–277.
Rawbone RG. Observations from six years’ experience of a health and safety research ethics committee. Bull Med Ethics 2000; 155:13–19.
Madsen SM, Holm S, Riis P. The extent of written trial information: preferences among potential and actual trial subjects. Bull Med Ethics 2000; 159:13–18.
Palmer AJM. Ethical appraisal of multicentre research: how should an LREC handle an MREC approved application? Bull Med Ethics 1998; 138:14–15.
Foster C. Will LRECs accept MRECs? Bull Med Ethics 1997; 133:15–16.
Boyce M. Observational study of 353 applications to London multicentre research ethics committee 1997–2000. Br Med J 2002; 325:1081.
Acknowledgements
I am grateful to Julie Wicks and Elizabeth Clark for help with data collection, and to Professor Terry Stacey, COREC, Dr Hugh Davies, Chairman London MREC, and current members of London MREC for agreeing to publication of this report. My views are not necessarily theirs. Some of the data presented here have been published as a short paper in the British Medical Journal [31]
Author information
Authors and Affiliations
Corresponding author
Additional information
The author was the principal investigator for one application but took no part in the discussion and decision. The author works for a contract research organization that is affiliated to the Association of the British Pharmaceutical Industry (ABPI).
Rights and permissions
About this article
Cite this article
Boyce, M. Observational study of 353 applications to the London multicentre research ethics committee, 1997–2000. International Journal of Pharmaceutical Medicine 16, 209–213 (2002). https://doi.org/10.1097/00124363-200210000-00002
Published:
Issue Date:
DOI: https://doi.org/10.1097/00124363-200210000-00002